Literature DB >> 36003182

Commentary: Another step forward ischemic mitral regurgitation comprehension.

Michele Di Mauro1,2, Stefano Guarracini2, Donato Capuzzi2, Antonio M Calafiore3.   

Abstract

Entities:  

Year:  2020        PMID: 36003182      PMCID: PMC9390775          DOI: 10.1016/j.xjon.2020.11.012

Source DB:  PubMed          Journal:  JTCVS Open        ISSN: 2666-2736


× No keyword cloud information.
Drs Di Mauro (MDM), Guarracini (SG), Capuzzi (DC), and Calafiore (AMC) The study by Aly and colleagues clearly demonstrates that ischemic mitral regurgitation is a complex disease that deserves valvular and subvalvular surgical approaches. See Article page 48. Ischemic mitral regurgitation (IMR) has been considered easily to treat, for years; indeed, the main surgical approach has been restrictive mitral annuloplasty (RMA), addressing just one of the actors involved in the pathophysiologic pathway leading from acute myocardial infarction to IMR., Unfortunately, IMR turned out to be more technical demanding, so the results of RMA have been scarce so far.3, 4, 5 In an attempt to improve the durability of mitral valve repair for IMR, many study groups are trying to better elucidate the right mechanisms underlying this disease. Recently, we published some articles, where even leaflets and chords postischemic modifications are summarized with relative mechanisms, further supporting the need for valvular and subvalvular approaches to improve outcomes. In this scenario, the animal-model study proposed by the Gorman Cardiovascular Research Group represents another step toward IMR comprehension. The great strength of this study is having employed a multimodal imaging approach to better understand the dynamics of mitral subvalvular apparatus in IMR. Recently, technology of cardiac imaging has advanced, and patients with cardiovascular disease have become increasing more complex. This has led to the integration of several different imaging techniques with a single aim: to clarify the mechanisms at the basis of the disease to guide treatment and predict prognosis. Aly and coworkers with this approach are able to demonstrate anterior leaflet area increment, reduction of posteromedial papillary muscle volume, and that the latter muscle mainly displaces horizontally and outward along the intercommissural axis. These findings confirm as IMR, especially high-grade, is the result of an unbalanced process starting after myocardial infarction.,, With this in mind, lone RMA cannot be the unique choice of treatment for IMR; valvular and subvalvular approaches have to deemed necessary.
  9 in total

Review 1.  The secret life of the mitral valve.

Authors:  Antonio M Calafiore; Antonio Totaro; Nicola Testa; Cosimo Sacra; Gaetano Castellano; Stefano Guarracini; Massimo Di Marco; Sotirios Prapas; Mario Gaudino; Roberto Lorusso; Domenico Paparella; Michele Di Mauro
Journal:  J Card Surg       Date:  2020-11-01       Impact factor: 1.620

2.  Mechanism of asymmetric leaflet tethering in ischemic mitral regurgitation: 3D analysis with multislice CT.

Authors:  Kitae Kim; Shuichiro Kaji; Yoshimori An; Hidetoshi Yoshitani; Masaaki Takeuchi; Robert A Levine; Yutaka Otsuji; Yutaka Furukawa
Journal:  JACC Cardiovasc Imaging       Date:  2012-02

3.  Mimicking natural mitral adaptation to ischaemic regurgitation: a proposed change in the surgical paradigm.

Authors:  Antonio M Calafiore; Antonio Totaro; Domenico Paparella; Mario Gaudino; Sotirios Prapas; Stephanie L Mick; Michele Di Mauro
Journal:  Eur J Cardiothorac Surg       Date:  2020-07-01       Impact factor: 4.191

Review 4.  Multimodality imaging assessment of mitral valve anatomy in planning for mitral valve repair in secondary mitral regurgitation.

Authors:  Romain Capoulade; Nicolas Piriou; Jean-Michel Serfaty; Thierry Le Tourneau
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

5.  Recurrent mitral regurgitation after annuloplasty for functional ischemic mitral regurgitation.

Authors:  Edwin C McGee; A Marc Gillinov; Eugene H Blackstone; Jeevanantham Rajeswaran; Gideon Cohen; Farzad Najam; Takahiro Shiota; Joseph F Sabik; Bruce W Lytle; Patrick M McCarthy; Delos M Cosgrove
Journal:  J Thorac Cardiovasc Surg       Date:  2004-12       Impact factor: 5.209

6.  Five-year echocardiographic results of combined undersized mitral ring annuloplasty and coronary artery bypass grafting for chronic ischaemic mitral regurgitation.

Authors:  Sandro Gelsomino; Roberto Lorusso; Giuseppe De Cicco; Irene Capecchi; Carlo Rostagno; Sabina Caciolli; Stefano Romagnoli; Ugo Da Broi; Pierluigi Stefàno; Gian Franco Gensini
Journal:  Eur Heart J       Date:  2007-11-07       Impact factor: 29.983

7.  Restrictive mitral annuloplasty cures ischemic mitral regurgitation and heart failure.

Authors:  Jerry Braun; Nico R van de Veire; Robert J M Klautz; Michel I M Versteegh; Eduard R Holman; Jos J M Westenberg; Eric Boersma; Ernst E van der Wall; Jeroen J Bax; Robert A E Dion
Journal:  Ann Thorac Surg       Date:  2008-02       Impact factor: 4.330

8.  Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation.

Authors:  Robert E Michler; Peter K Smith; Michael K Parides; Gorav Ailawadi; Vinod Thourani; Alan J Moskowitz; Michael A Acker; Judy W Hung; Helena L Chang; Louis P Perrault; A Marc Gillinov; Michael Argenziano; Emilia Bagiella; Jessica R Overbey; Ellen G Moquete; Lopa N Gupta; Marissa A Miller; Wendy C Taddei-Peters; Neal Jeffries; Richard D Weisel; Eric A Rose; James S Gammie; Joseph J DeRose; John D Puskas; François Dagenais; Sandra G Burks; Ismail El-Hamamsy; Carmelo A Milano; Pavan Atluri; Pierre Voisine; Patrick T O'Gara; Annetine C Gelijns
Journal:  N Engl J Med       Date:  2016-04-03       Impact factor: 91.245

9.  Mid-term echocardiographic results with different rings following restrictive mitral annuloplasty for ischaemic cardiomiopathy.

Authors:  Francesco Onorati; Antonino Salvatore Rubino; Domenico Marturano; Eugenia Pasceri; Giuseppina Mascaro; Stefania Zinzi; Filiberto Serraino; Attilio Renzulli
Journal:  Eur J Cardiothorac Surg       Date:  2009-05-02       Impact factor: 4.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.